AUTHORS
Simo Du, MD,MHS, Muthu Kumaran, MD2, Tiantian Zhang, MD, PhD3, Sharmilan Thanendrarajan, MD4, Jiahao Peng5, Yuqing Wang6, Frits van Rhee, MD, PhD7
AFFILIATIONS
1 University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
2 University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
3 University of Central Florida, Pensacola, Florida, United States
4 University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
5 Westchester Medical Center, Valhalla, United States
6 Westchester Medical Center, Valhalla, United States
7 University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, United States
ABSTRACT
Background:
Hematopoietic stem cell transplantation (HSCT) remains a cornerstone therapy for transplant-eligible patients with multiple myeloma (MM). Prior studies have identified disparities in HSCT utilization by race, socioeconomic status, and treatment facility, largely in older or unstratified populations. However, whether these determinants vary across the lifespan, particularly in early-onset MM, and whether the survival association of HSCT differs by age remain unknown.
Methods:
We conducted a retrospective cohort study of adults with MM (ICD-O-3 histology 9732) diagnosed between 2004 and 2024 in the National Cancer Database. Patients were stratified as early-onset (<40 years), middle-aged (40–64 years), or older (≥65 years). The primary outcome was receipt of upfront HSCT. Multivariable logistic regression was performed within each age stratum, adjusting for demographics, socioeconomic status, geographic region, facility type, Charlson-Deyo score, and year of diagnosis. Overall survival (OS) was evaluated using Cox models within each stratum with the same covariates. Effect modification was assessed in a pooled model with a HSCT -by-age group interaction term.
Results:
Among 308,771 patients with MM, 62,107 (20.1%) underwent HSCT. Utilization declined with age: 1,522 of 3,877 patients aged <40 years (39.3%), 40,057 of 118,093 aged 40–64 years (33.9%), and 20,528 of 186,788 aged ≥65 years (11.0%).
Black race, insurance status, treatment facility type, and comorbidity burden were the strongest independent predictors of HSCT across all strata. Among patients aged <40 years, Black race (adjusted OR [aOR], 0.73; 95% CI, 0.62–0.85; P<0.001) and female sex (aOR, 0.76; 95% CI, 0.67–0.87; P<0.001) were associated with lower odds of transplantation; female sex was not associated among those aged 40–64 years (aOR, 0.98; 95% CI, 0.96–1.01; P=0.174). Compared with uninsured patients, privately insured patients had more than fourfold higher odds of transplantation (aOR, 4.39; 95% CI, 3.04–6.34; P<0.001), with similar disparities in other strata.
Treatment at an academic/research program was strongly associated with transplantation, with effects more pronounced with advancing age (aOR, 5.41 [4.87–6.01] for 40–64 years; 7.33 [6.46–8.32] for ≥65 years; both P<0. 001.Comorbidity showed a graded inverse association in the two older strata, whereas among patients aged <40 years only a Charlson-Deyo score ≥3 reduced transplant odds (aOR, 0.43; 95% CI, 0.25–0.75; P=0.003), with no significant association at lower comorbidity levels. Area-level income and education were associated with transplant receipt in the two older strata but not among patients aged <40 years. Year of diagnosis predicted transplantation among older patients, with odds approximately doubling after 2016 relative to 2004. No comparable temporal trend was observed among patients aged <40 years.
Transplantation was independently associated with superior OS across all age groups (adjusted HR, 0.60 [95% CI, 0.52–0.68] for <40 years; 0.56 [95% CI, 0.54–0.57] for 40–64 years; and 0.35 [95% CI, 0.34–0.36] for ≥65 years; all P<0.001),and this association differed significantly by age (interaction P<0.001), with the greatest relative survival advantage observed among older adults.
Conclusions:
Receipt of HSCT remains strongly influenced by non-clinical factors across the age spectrum. Black patients had approximately 25–30% lower adjusted odds of transplantation in every stratum, and insurance status was associated with up to a fourfold difference, independent of comorbidity, socioeconomic status, geography, and facility characteristics.
Patients diagnosed before age 40 showed a distinct pattern: comorbidity influenced transplant receipt only at the highest burden, and area-level socioeconomic measures were not associated with transplantation, though insurance status remained a strong determinant. The absence of a temporal trend in this group contrasts with the progressive increase observed in older patients, consistent with expanding transplant eligibility in older adults over the study period.
Transplantation was associated with improved survival at all ages, with the greatest relative benefit among patients aged ≥65 years. This should be interpreted cautiously, as it may reflect more stringent selection of older recipients and residual confounding by unmeasured fitness and disease severity rather than true age-dependent treatment effect.
DISCLOSURES
Simo Du, MD,MHS: No relevant conflicts of interest to declare.